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Abstract
Purpose Cancer-related fatigue (CRF) is a frequent and
distressing symptom experienced after cancer treatment.
RESTORE is the first web-based resource designed to en-
hance self-efficacy to manage CRF following curative-intent
treatment. The aim of this study is to test the proof of concept
and inform the design of an effectiveness trial.
Methods A multi-centre parallel-group two-armed (1:1) ex-
ploratory randomised controlled trial (RCT) with qualitative
process evaluation was employed in the study. Participants
(≥18 years; ≤5 years post treatment with moderate to severe
fatigue) were recruited and randomly assigned to RESTORE
or a leaflet. Feasibility and acceptability were measured by
recruitment, attrition, intervention adherence, completion of
outcome measures and process evaluation. Change in self-
efficacy to manage CRF was also explored. Outcome mea-
sures were completed at baseline (T0), 6 weeks (T1) and
12 weeks (T2). Data were analysed using mixed-effects linear
regression and directed content analysis.
Results One hundred and sixty-three people participated in
the trial and 19 in the process evaluation. The intervention
was feasible (39 % of eligible patients consented) and accept-
able (attrition rate 36%). There was evidence of higher fatigue
self-efficacy at T1 in the intervention group vs comparator
(mean difference 0.51 [−0.08 to 1.11]), though the difference
in groups decreased by 12 weeks. Time since diagnosis influ-
enced perceived usefulness of the intervention. Modifications
were suggested.
Conclusion Proof of concept was achieved. The RESTORE
intervention should be subject to a definitive trial with some
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adjustments. Provision of an effective supportive resource
would empower cancer survivors to manage CRF after treat-
ment completion.
Trial registration ISRCTN67521059
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Background
With improvements in cancer detection and treatment, the
number of cancer survivors is steadily rising [1]. However,
the consequences of cancer and its treatment can have a sig-
nificant impact on health services and individuals’ daily lives
[2]. There is growing demand for tailored resources to support
survivors to live with the consequences of cancer, including
supported self-management, to address individual needs [3].
Cancer-related fatigue (CRF) is a frequently reported and
distressing symptom [4], is associated with depression [5] and
can persist for years [6] after treatment completion. CRF can
be difficult to manage; pharmacological solutions have limited
effect and there has been a call for non-pharmacological inter-
ventions [7]. Physical activity [8], cognitive behaviour therapy
and psychosocial support [9] may improve CRF, but existing
programmes are not accessible to many and often require sig-
nificant input from trained professionals to deliver them.
Evidence is growing that Internet-based interventions can
help people manage physical symptoms [10]. The Internet can
reach a large population in a cost-effective way: 87 % of the
British and 74 % of the US populations have access to the
Internet with the over 50s being the fastest growing group [11,
12]. Furthermore, with changes in cancer aftercare, particular-
ly a move towards supported self-management, resources to
support patients to self-manage are of utmost importance.
Foster and Fenlon [13] devised a conceptual framework of
recovery of health and wellbeing following cancer treatment
which assumes that cancer and its treatment disrupt people’s
lives, and requires a process of recovery. The framework is
underpinned by principles of self-efficacy theory [14]. Belief
in one’s ability to manage consequences of cancer and its
treatment may be low after treatment [15], and support to
enhance self-efficacy to live with problems, and thus improve
health and wellbeing, is likely to be an important part of re-
covery. Few web-based interventions for cancer survivors
consider CRF [16, 17], and none have explicitly attempted
to improve self-efficacy to self-manage CRF.
Interventions designed to increase self-efficacy to manage
physical symptoms have been shown to be effective in
chronic-disease populations, and several self-management
programmes are designed to enhance self-efficacy [18].
Increased self-efficacy to manage a symptom may alter a per-
son’s perception of that symptom, making it feel less
bothersome to everyday life, thus enhancing quality of life
(QoL) [19].
The aim of this exploratory randomised controlled trial
(RCT) and process evaluation was to test the proof of concept
of RESTORE, a web-based resource designed to increase self-
efficacy to manage CRF. Proof of concept was tested by ex-
ploring feasibility, acceptability and potential to increase self-
efficacy to self-manage CRF following primary cancer treat-
ment. Data from this study will also inform a sample size
calculation for a full-scale effectiveness RCT. Participants
were introduced to the trial in secondary care to test the feasi-
bility of embedding the resource in this context. This paper
presents findings of the exploratory RCT, following
Consolidated Standards of Reporting Trials (CONSORT)
guidelines [20] and informed by Standard Protocol Items:
Recommendations for Interventional Trials (SPIRIT) guid-
ance for clinical trials [21]. Impact on health care resource
use will also be explored.
Methods
The intervention
RESTORE was developed using LifeGuide open-source soft-
ware [22]. Full details of the development of RESTORE are
provided elsewhere [23].
RESTORE consisted of five sessions informed by
Macmillan Cancer Backup’s leaflet, Coping with Fatigue
[24]; self-efficacy theory; cognitive behavioural therapy; and
evidence of fatigue management in cancer survivors. The con-
tent of RESTORE is described elsewhere [25]. Briefly, partic-
ipants were limited to 6 weeks access to RESTORE and pre-
sented with sessions at weekly intervals. Sessions 1 and 2
were mandatory and introduced CRF and goal setting. For
the next 3 weeks, participants chose from (i) diet, sleep, exer-
cise, home and work life; (ii) thoughts and feelings; and (iii)
talking to others. Participants can choose to complete all avail-
able sessions or spend more time on the area/s most important
to them. Structured activities were available throughout in-
cluding goal setting, automated tailored feedback on achieve-
ment of goals and fatigue level, and videos of patient stories.
Participants were also encouraged to download and complete
a fatigue diary.
Design
A parallel-group two-armed (1:1) exploratory RCT with
a qualitative process evaluation was employed.
Participants were randomised to RESTORE or the
leaflet.
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Participants
Eligible participants were ≥18 years, had clinical diagnosis of
invasive cancer ≤5 years previously, had completed curative-
intent treatment (surgery/cytotoxic chemotherapy/radiotherapy),
had no evidence of metastatic disease, self-reported moderate to
severe fatigue (fatigue of ≥4 on an 11-point rating scale) [26] and
had access to the Internet and an email account or willing to
create an email account. Individuals were excluded if their clin-
ical care team deemed them unable to give informed consent,
they had a mental health condition likely to be exacerbated by
participation or they were too ill to engage in the study.
Procedures
Approvals were granted by the National Research Ethics
Service Committee (REC: 12/SC/0374) and University
Hospital Southampton NHS Foundation Trust (REF RHM
CAN0875).
Participants were recruited between September 2012 and
May 2013 from 12 sites across the UK. Medical details were
collected for all consented participants. Reasons for non-
participation were recorded wherever possible.
A subsample of participants were invited by email to take
part in the process evaluation. A maximum-variation sample
was drawn across trial arms, participating sites and a range of
individual characteristics (gender, age, adherence with
RESTORE).
Data collection
During screening, date of birth, sex and cancer type were
recorded. Participants provided informed consent and com-
pleted baseline (T0) questionnaires online. Information from
clinical records included cancer diagnosis (date and type) and
treatments received.
The RESTORE group received automated weekly emails
announcing the availability of their next session and reminders
if they had not accessed the session within 7 days. Participants
completed further questionnaires at 6 (T1) and 12 weeks (T2)
post baseline. RESTORE was available to both groups after
completion of T2 questionnaires.
Process evaluation interviews, conducted by telephone af-
ter T2 assessments, were recorded and transcribed verbatim.
Pseudonyms replaced names.
Measures
The following validated measures were assessed at each time
point:
& Perceived Self-efficacy for Fatigue Self-management
(PSEFSM) includes 6 items assessing degree of self-
efficacy in performing various tasks on an 11-point scale
(score 0–10; higher scores=greater self-efficacy). This
measure has good reliability (Cronbach’s coefficient of
0.92), construct validity and generalisability [27].
& Cancer Survivors’ Self-efficacy Scale (CS-SES) [28] is an
11-item scale, based on Lorig’s 6-item Chronic Disease
Self-efficacy Scale [29]. Participants rate their confidence
in performing various disease-related activities (scale of
0–10; higher score=higher self-efficacy).
& Functional Assessment of Cancer Therapy—General
(FACT-G) [30] is a 27-item questionnaire consisting of 4
subscales: physical, social, emotional and functional
wellbeing (total score of 0–108; higher scores=better
QoL).
& Personal Wellbeing Index (PWI) [31] includes 7 items
related to ‘How satisfied are you with your life as a
whole?’ Response options are 0 to 10 (higher score=
higher satisfaction with life; scale 0–100).
& Patient Health Questionnaire (PHQ-9) [32] is a 9-item
scale based on the diagnostic criteria for depressive disor-
der measuring symptoms/functional impairment and se-
verity (total score range 0–27; higher score=greater
depression).
& Brief Fatigue Inventory (BFI) [33] is a 9-item scale
assessing current, usual and worst levels of fatigue (in
the past 24 h) and the extent to which fatigue interferes
with everyday life (scale of 0–10; higher scores=more
fatigue). A cut-off of ≥7 denotes ‘severe’ fatigue [33].
Intervention adherence was examined by usage data.
Accessing session 3 was chosen as the cut-off for adherence
as this is where participants begin to set goals and engage with
other activities not available in the leaflet. Data on health
service use was collected by bespoke patient questionnaire.
Finally, process evaluation interviews explored feasibility
and acceptability of the trial [34], e.g. the perceived usefulness
of RESTORE/leaflet, the work required to complete the study
and suggested improvements to RESTORE.
Sample size
A formal sample size calculation was inappropriate for this
exploratory RCT; a sample of 125 was chosen pragmatically,
based on resources and time available. Estimated attrition was
20 %.
Randomisation
A statistician independently generated a random allocation
sequence, using ‘R’ for each NHS centre, and participants
were randomised in blocks of four [20]. Participants were
randomised by the research team after completion of T0
Support Care Cancer
questionnaires. Statisticians andmembers of the research team
not involved in recruitment were blinded during analysis.
Analysis
Feasibility of RESTORE was assessed by recruitment rates,
reasons for non-participation and attrition. Acceptability was
inferred by adherence with the intervention and questionnaire
completion rates. Feasibility and acceptability were further
explored in the process evaluation. Transcripts were analysed
using directed content analysis within a framework approach.
The potential for RESTORE to improve self-efficacy was
examined by a mixed-effects model for fatigue self-efficacy
with a random intercept for centre (to account for within-
centre correlation) and random coefficients for time (to ac-
count for within-person correlation). The effect of group
(comparator vs intervention) in this model was of primary
interest. Analyses were based on intention-to-treat.
Health economic analysis identified health care resource
use across groups and is reported using descriptive statistics.
Results
Participants
Figure 1 shows patient flow through the study. Three partici-
pants consented but did not complete a T0 questionnaire (not
randomised). Recruitment was faster than expected and 163
participants were randomised, 85 allocated to RESTORE and
78 the leaflet. (See Table 1 for sample characteristics.) Four
participants experienced a recurrence during the study and
were excluded from analysis.
Nineteen of the 81 invited participants completed a process
evaluation interview, 8 from RESTORE and 11 from the com-
parator group. Most (n=15) were female and ≤60 years (n=
14, age range 39–78 years). A range of cancer types were
represented; the majority (n=12) had breast cancer. Six in
the RESTORE group had accessed ≥3 RESTORE sessions.
Feasibility
One hundred and sixty-three participants were recruited, an
average of five participants per week. Forty-one percent of
eligible participants consented to the study (16 % of those
screened). Nine percent of patients screened were ineligible
due to a lack of access to a computer/Internet, and a further
1 % declined due to the web-based nature of the study.
Randomisation worked well; baseline characteristics were
generally well-balanced between groups (Table 1). However,
the intervention group had a higher proportion ‘not working’
(48.8 vs 36.0 %), primarily due to more retired people in this
group, and a greater number of days since last cytotoxic treat-
ment (577.71 vs 484.61).
No process evaluation participants reported having to learn
new skills to use RESTORE. However, concerns were raised
that older people might struggle if they did not use computers
regularly. Some participants encountered problems navigating
RESTORE, experienced difficulties logging on, had password
refused and reported screens freezing or closing down
unexpectedly.
Acceptability
Half of participants in the process evaluation felt the timing of
participation was ‘about right’. The remainder would have
preferred RESTORE sooner. They were ≥1 year from diagno-
sis and suggested benefits of participating before treatment
completion.
Most participants identified benefits of taking part in the
trial, including feeling supported and reassured that someone
was interested in their condition. A number made positive
changes to their lifestyle as a result of using RESTORE or
the leaflet. For some, RESTORE had improved their under-
standing of CRF and how to manage it; for others, involve-
ment in the trial offered a period of reflection and allowed
them to re-evaluate what they could do. Most reported an
increase in confidence to self-manage the effects of CRF and
considered their CRF to be less bothersome.
Of those who accessed both RESTORE and the leaflet, half
preferred RESTORE, finding it more flexible and interactive.
Others felt the leaflet was more convenient as it was immedi-
ately available and could be consulted any time.
Suggested improvements to the intervention included pro-
viding more cancer-specific information and more
personalised feedback.
Total attrition rate (consent to T2) was 36 %. Nine people
(5.5 %) actively withdrew and 36 (22.1 %) did not complete
follow-up questionnaires. Seven participants from the
RESTORE group, and 2 from the comparator group missed
T1 but completed T2 questionnaires. Four people were exclud-
ed due to metastatic disease. No adverse events were reported.
Seventy-one percent of participants were deemed to have
adhered with the intervention (logged on to sessions 1 and 2
and a third session). Sixty percent logged on to four sessions,
43 % to five sessions. The Work and home life session was the
most visited (51 % of participants) of the three ‘optional’ ses-
sions, and Talking to others was the least visited (27 % of par-
ticipants). Within sessions 3–5, participants engaged most with
the goal-setting section and least with the goal review section.
Potential to increase self-efficacy to manage CRF
Missing data were handled using multiple imputation where
appropriate. Ninety-seven (61.0 %) complete cases were
Support Care Cancer
observed and 130 (81.8 %) people had ≤6 missing values.
Imputation models were constructed for all outcomes at each
time point. As a typical example, the imputation model for
fatigue self-efficacy at T1 included fatigue self-efficacy at
baseline and T2, each of the other outcomes at T1, centre,
group, age, gender and time since last treatment.
Examination of partial correlations between all outcomes sug-
gested the inclusion of baseline values of fatigue self-efficacy
Fig. 1 Patient flow
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and BFI in each imputation model. Time since last treatment
also required multiple imputation (missing n=15 [9.4 %]); the
imputation model included all baseline values of outcomes,
centre, group, age and gender.
Multiple imputation was performed using Stata 12.1.
Predictive mean matching was used to ensure feasible
values of the outcomes, with imputations drawn from
the nearest three neighbours. Inspection of histograms
suggested observed and imputed values had similar
distributions.
The intended analysis (between-group, repeated-measures
model with random intercept for centre and random coeffi-
cients for time) could not be implemented due to failure of
the model to converge; we believe the highly variable nature
of how fatigue evolves over time in an individual is the reason
for this. Instead, simpler mixed-effects models were used to
assess the effect of the intervention on outcomes at T1 and T2
separately (controlling for baseline scores and with a random
intercept for centre).
Table 2 shows mean scores for all outcome measures over
the three time points. There is evidence of improved fatigue
self-efficacy at T1 (0.514, 95 % CI [−0.084, 1.112], P=0.09),
in the RESTORE group though the impact is lost by T2. There
is no evidence of difference between groups for any other
outcomes.
The pattern of fatigue self-efficacy for adherent and non-
adherent individuals was similar to the patterns observed for
the RESTORE and comparator groups: T0 5.466 (1.944) vs
5.028 (1.827) and T1 6.520 (1.789) vs 5.250 (1.250).
Based on data observed, a sample of at least 317 per group
would be required to detect a standardised effect size of 0.5
(significance level 5 % and power of 90 %).
Table 1 Baseline characteristics
of RESTORE and comparator
groups
All (n=159) RESTORE
(n=83)
Comparator
(n=76)
Gender, n (%) Male 37 (23.3) 22 (26.5) 15 (19.7)
Female 122 (76.7) 61 (73.5) 61 (80.3)
Age Range 29–80 29–78 35–80
Mean (SD) 57.8 (9.95) 58.1 (10.7) 57.5 (9.1)
Ethnicity, n (%) White 156 (98.7) 81 (97.6) 75 (100)
Non-white 2 (1.3) 2 (2.4) 0 (0)
IMD quintile (England only;
n=140), n (%)
1 (most deprived) 16 (11.4) 7 (9.5) 9 (13.6)
2 23 (16.4) 13 (17.6) 10 (15.2)
3 34 (24.3) 19 (25.7) 15 (22.7)
4 34 (24.3) 18 (24.3) 16 (24.2)
5 33 (23.6) 17 (23.0) 16 (24.2)
Employment status, n (%) Employed 90 (57.8) 42 (51.2) 48 (64.0)
Unemployed 67 (42.2) 40 (48.8) 27 (36.0)
Other long-term conditions, e.g.
diabetes, asthma; n (%)
0 54 (34.0) 28 (33.7) 26 (34.2)
1 54 (34.0) 27 (32.5) 27 (35.5)
2 29 (18.2) 18 (21.7) 11 (14.5)
>2 22 (13.8) 10 (12.0) 12 (15.8)
Cancer type, n (%) Breast 94 (59.1) 46 (55.4) 48 (63.2)
GI 25 (15.7) 14 (16.9) 11 (14.5)
Bladder/kidney 1 (0.6) 0 (0) 1 (1.3)
Gynaecological 8 (5.0) 5 (6.0) 3 (3.9)
Head and neck 15 (9.4) 10 (12.0) 5 (6.6)
Lung 2 (1.3) 0 (0) 2 (2.6)
Prostate 14 (8.8) 8 (9.6) 6 (7.9)
Treatment type, n (%) Chemotherapy 110 (69.2) 52 (62.7) 58 (76.3)
Radiotherapy 109 (68.6) 53 (63.9) 56 (73.7)
Surgery 135 (84.9) 71 (85.5) 64 (84.2)
Hormone/endocrine 74 (46.5) 37 (44.6) 37 (48.7)
Time since diagnosis (days) 771 (569) 768 (584) 773 (557)
Time since last cytotoxic
treatment (days)
531 (524) 578 (622) 485 (405)
IMD index of multiple deprivation
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Health resource use
There was a high proportion of missing health economic data,
making an economic evaluation challenging and formal sta-
tistical comparisons impossible. Examination of available de-
scriptive data suggests comparable use of resources between
groups: mean number of visits to a GP practice at T2 2.29
(1.27) in the RESTORE and 1.90 (1.04) in the comparator
groups, and 1.41 (0.80) and 1.29 (1.27) visits to the oncologist
respectively.
Discussion
The primary aim of the study was to test proof of concept by
establishing the feasibility and acceptability of RESTORE and
the potential to improve fatigue self-efficacy following treat-
ment with curative intent. The intervention was found to be
feasible and acceptable and established proof of concept.
Uptake of the intervention was high (39 %) compared to that
of similar interventions [35], suggesting a demand for sup-
portive resources in this population. Although not powered
to detect change, there was evidence of higher fatigue self-
efficacy at T1 in the RESTORE group compared with the
comparator group, though improvements in the comparator
group meant the difference between groups was negligible
by 12 weeks.
Participants in the process evaluation did not have to learn
new skills to take part but felt those less familiar with the
Internet would need support. Dropout was higher in the
RESTORE arm and this may be because they struggled with
the web-based nature of the trial.
Despite being a problem that is widely reported dur-
ing treatment and in the year following treatment [7,
36], fatigue is not routinely assessed or discussed. In
this study, many people were experiencing fatigue in
the years following treatment and found participation
in the trial beneficial as an acknowledgement of their
fatigue and its impact. This complements results from
Yun et al. [16] who describe the only other web-based
intervention for CRF, reporting improvements in CRF
following a 12-week education programme.
There appears to be no discernible pattern to fatigue self-
efficacy over time in this sample. This may in part be due to
the complex nature of CRF and the wide range of time since
treatment completion (≤5 years). For some, fatigue may be
relatively short-lived; for others, it may have persisted for
several years. Those with long-standing fatigue are likely to
have tried a number of different strategies to manage their
CRF. Other studies have identified the process of trial and
error in relation to self-management of chronic conditions
[37]. Therefore, timing of an intervention like RESTORE is
likely to be highly important. Our results suggest that offering
RESTORE soon after treatment completion may have the
greatest benefit.
Table 2 Means, standard deviation and estimated group effects for fatigue self-efficacy and all secondary outcome measures
Time point Mean (SD) Group effect (95 % CI) P
RESTORE Comparator
Fatigue self-efficacy (range 1–11)a T0 5.376 (1.930) 5.373 (2.048) – –
T1 6.421 (1.781) 5.904 (2.107) 0.514 (−0.084, 1.112) 0.09
T2 6.439 (2.228) 6.294 (2.207) 0.106 (−0.427, 0.638) 0.70
Cancer survivor self-efficacy (range 0–10)a T0 6.79 (1.58) 6.68 (1.75) – –
T1 7.13 (1.57) 7.05 (1.63) 0.026 (−0.359, 0.411) 0.90
T2 7.35 (1.79) 7.23 (1.77) 0.160 (−0.235, 0.556) 0.43
Brief Fatigue Inventory (range 0–10) T0 5.41 (1.86) 5.41 (1.96) – –
T1 5.08 (2.39) 4.62 (2.17) 0.353 (−0.293, 0.999) 0.28
T2 4.34 (2.50) 4.36 (2.36) −0.239 (−0.938, 0.459) 0.50
Personal Wellbeing Index (range 0–100)a T0 64.9 (17.2) 63.0 (19.8) – –
T1 65.3 (19.1) 64.6 (18.6) 0.622 (−3.437, 4.682) 0.76
T2 63.8 (21.8) 65.1 (24.1) 0.244 (−5.687, 6.175) 0.94
FACT-G (range 0–108)a T0 72.9 (16.2) 71.4 (17.8) – –
T1 74.1 (18.0) 76.9 (17.4) −2.206 (−5.503, 1.091) 0.19
T2 75.0 (19.4) 78.7 (18.5) −3.034 (−6.639, 0.571) 0.10
PHQ-9 (range 0–27) T0 9.77 (5.50) 8.96 (5.66) – –
T1 8.41 (5.58) 7.74 (5.82) −0.452 (−1.761, 0.858) 0.50
T2 8.59 (6.37) 6.82 (5.50) 0.676 (−0.880, 2.231) 0.40
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More people are turning to the Internet for health-related
information but the need to reduce digital exclusion is
recognised [38]. Only 9 % of those screened for this study
were deemed ineligible due to a lack of computer or Internet
access; nevertheless, our results suggest some individuals
have a preference for written media. Individual preferences
are likely to be important for the success of resources such
as RESTORE and need to be considered in future work—e.g.
asking people if they would prefer web-based, leaflet or a
combination.
RESTORE appeared to have additional benefits when com-
pared to the leaflet through the accessibility of the resource and
the structured activities. There was evidence that participants
engaged with RESTORE and gained benefit from doing so, in
particular the goal-setting sections and interactive nature of the
intervention. These components have been shown to be effective
in other studies [39]. Some participants were more adherent than
others, and these individuals appear to have yielded more benefit
although a larger trial will enable us to test this.
The proportion of missing data across outcome measures
was consistent, suggesting no single measure is particularly
(un)suitable as a primary outcome in a future study, though
methods to reduce missing data rates will be required. Low
completion rates of economic data suggest these data collec-
tion methods should be simplified or condensed through, for
example, use of alternative sources of routinely collected data
such as Hospital Episode Statistics.
Participant dropout was higher than expected (particularly in
the RESTORE group) and higher than reported in comparable
studies [16, 17]. This was explored in the process evaluation
where some areas of improvement were identified, e.g. timing
and choice of paper-based and web-based content. Measures to
improve engagement with the resource need to be further ex-
plored. Higher dropout rates are not unusual for web-based in-
tervention studies [40]. Reasons cited for this include the severity
and chronic nature of the condition [41], loss of interest and
salient content. However, there is a paucity of data on approaches
to sustain usage, and some data suggest participants who drop
out may still benefit from the intervention [42].
Limitations
This study has a number of limitations. We compared
RESTORE against a leaflet which was also an intervention.
Our rationale for doing this was the importance of determining
if RESTORE is likely to yield greater benefits than an existing
resource. However, we were unable to restrict independent ac-
cess to a publicly available resource by the RESTORE group. In
addition, it was not possible to blind participants to group allo-
cation. Additionally, we worked closely with recruiting sites
through study days to talk through study processes and proce-
dures. We involved people affected by CRF and they gave pow-
erful accounts of their experiences of CRF. This raised awareness
of CRF among research nurses who had not considered this to be
a significant problem, and consequently, there were several re-
ports of changes in practice. Process evaluation results should be
interpreted with caution due to the low response rate. Finally,
external generalisability is affected by the larger proportion of
women (and participants with breast cancer) in the study.
The findings from this exploratory trial suggest that
RESTORE is feasible and acceptable and warrants testing in
a larger efficacy trial. However, a number of refinements to
RESTORE are required before testing its effectiveness in a
large trial, for example including cancer-site-specific informa-
tion, providing more personalised feedback on progress and
targeting the intervention for participants within 12 months of
treatment completion. This is a potentially important form of
support for the growing numbers of cancer survivors living
with and managing consequences of cancer and its treatment.
Abbreviations: BFI Brief Fatigue Inventory, CONSORT
Consolidated Standards of Reporting Trials, CRF Cancer-
related fatigue, CS-SES Cancer Survivors’ Self-efficacy Scale,
FACT-G Functional Assessment of Cancer Therapy—General,
IMD Index of Multiple Deprivation, PHQ-9 Patient Health
Questionnaire-9 item scale, PSEFSM Perceived Self-efficacy
for Fatigue Self-management, PWI Personal Wellbeing Index,
QoL quality of life, RCT randomised controlled trial, SPIRIT
Standard Protocol Items: Recommendations for Interventional
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